1-methyl-3-(4-(trifluoromethyl)phenyl)urea | 23747-91-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-3-(4-(trifluoromethyl)phenyl)urea
• 英文别名: 1-Methyl-3-[4-(trifluoromethyl)phenyl]urea
• CAS: 23747-91-3
• 化学式: C₉H₉F₃N₂O
• mdl: MFCD24389305
• 分子量: 218.178
• InChiKey: JGORTQYGAODLEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-methyl-3-(4-(trifluoromethyl)phenyl)urea 在 sodium periodate 作用下， 以 乙醇 、 苯 为溶剂， 反应 1.0h， 生成 1'-Methyl-3'-[4-(trifluoromethyl)phenyl]spiro[2-benzofuran-3,5'-imidazolidine]-1,2',4'-trione
  参考文献：
  名称：

  Synthesis and anticonvulsant activity of new N-1′,N-3′-disubstituted-2′H,3H,5′H-spiro-(2-benzofuran-1,4′-imidazolidine)-2′,3,5′-triones

  摘要：

  Thirteen new N-1',N-3'-disubstituted-2'H,3H,5'H-spiro-(2-benzofuran-1,4'-imidazolidine)-2',3,5-triones were synthesized and their pharmacological activity determined with the objective to better understand their SAR for anticonvulsant activity. The anticonvulsant effects of these compounds were evaluated by standard pentylenetetrazol (scPTZ test) and maximum electroshock seizure (MES test) models in mice. Most of the compounds showed ability to protect against the pentylenetetrazol-induced convulsions. Compound 3o (the N-1'-p-nitrophenyl, N-3'-ethyl derivative) in the N-1'-aryl, N-3'-alkyl disubstituted series exhibited maximum activity with ED50 of 41.8 mg/kg in scPTZ convulsion model. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.102
• 作为产物：
  描述：

  甲胺 、 4-三氟甲基苯基异氰酸酯 以 甲苯 为溶剂， 生成 1-methyl-3-(4-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  1,3,5-和1,3,5,5-取代的巴比妥酸酯的多组分一锅顺序合成。

  摘要：

  碳二亚胺和丙二酸单乙酯容易反应，得到N-酰脲衍生物，可以通过添加合适的碱原位环化。该方法代表在非常温和的条件下（有机溶剂/ 2 N NaOH水溶液，20摄氏度）进行的简单直接的一锅顺序合成1,3,5-三取代的巴比妥酸盐。在亲电子试剂的存在下进行反应，通过三组分一锅法连续反应形成了完全取代的（即1,3,5,5-四取代的）巴比妥酸酯。然而，后者仅在高反应性亲电试剂例如苄基和在某些情况下是烯丙基卤的情况下发生。为了扩大该方法的范围，我们寻求开发一种用于1,3,5-三取代的巴比妥酸酯的C-烷基化的通用方法。我们发现，在无水K2CO3存在下于120℃下在CH3CN中用烷基卤处理1,3,5-三取代的巴比妥酸酯时发生C-烷基化，从而以良好的收率提供目标1,3,5,5-四取代的巴比妥酸酯。多组分工艺是通过以下三个步骤以一锅顺序方式组合完成的，即碳二亚胺与丙二酸单乙酯的缩合，所得N-酰基脲的环化以及所得1,3的C-烷基化，

  DOI：

  10.1021/jo801288s

文献信息

• Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents
  申请人：Sattigeri Vishwajanani Jitendra

  公开号：US20090048186A1

  公开（公告）日：2009-02-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了含有本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• [EN] PESTICIDAL COMPOUNDS<br/>[FR] COMPOSÉS PESTICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2016012333A1

  公开（公告）日：2016-01-28

  A method of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula (I), wherein R1 is R4, YR5 or ZR6; Y is CO or C=S; Z is S, S(O), SO2 or PO2; and A is an optionally substituted phenyl or an optionally substituted heteroaromatic ring, wherein R1 to R6 are defined organic groups; new compounds are also provided.

  一种用于对抗和控制昆虫、螨虫、线虫或软体动物的方法，包括向害虫、害虫栖息地或易受害虫攻击的植物施加化学式(I)中的一种化合物的杀虫、杀螨、杀线虫或杀软体动物有效量，其中R1为R4、YR5或ZR6；Y为CO或C=S；Z为S、S(O)、SO2或PO2；A为一个可选择取代的苯基或可选择取代的杂环，其中R1至R6为定义的有机基团；还提供了新的化合物。
• [EN] QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF<br/>[FR] DÉRIVÉS DE QUINAZOLINONES POUR LE TRAITEMENT DE LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2022003712A1

  公开（公告）日：2022-01-06

  The present invention described herein relates to a compound having Structure I for treating diseases and disorders for which inhibition or modulation of the Ubiquitin Ligase COP1 enzyme produces a physiologically beneficial response, in particular for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). These compounds having Structure I arecapable of increasing the level of adipose triglyceride lipase (ATGL). Also provided is the process of preparing compounds having Structure I.

  本发明描述了一种具有结构I的化合物，用于治疗通过抑制或调节泛素连接酶COP1酶产生生理上有益反应的疾病和紊乱，特别是用于治疗非酒精性脂肪肝病（NAFLD）。这些具有结构I的化合物能够增加脂肪三酸甘油酯脂解酶（ATGL）的水平。还提供了制备具有结构I的化合物的方法。
• DE1802739
  申请人：——

  公开号：——

  公开（公告）日：——
• Antibacterial Agents
  申请人：Meutermans Wim

  公开号：US20090023669A1

  公开（公告）日：2009-01-22

  The present invention, in one aspect, provides a method of inhibiting bacterial growth by contacting bacteria with an effective amount of at least one monosaccharide compound of formula (1) as described herein: